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Segmental copy-number variations (CNVs) in the human genome are associated with developmental disorders and
susceptibility to diseases. More importantly, CNVs may represent a major genetic component of our phenotypic diversity.
In this study, using a whole-genome array comparative genomic hybridization assay, we identified 3,654 autosomal
segmental CNVs, 800 of which appeared at a frequency of at least 3%. Of these frequent CNVs, 77% are novel. In the
95 individuals analyzed, the two most diverse genomes differed by at least 9 Mb in size or varied by at least 266 loci in
content. Approximately 68% of the 800 polymorphic regions overlap with genes, which may reflect human diversity in
senses (smell, hearing, taste, and sight), rhesus phenotype, metabolism, and disease susceptibility. Intriguingly, 14 poly-
morphic regions harbor 21 of the known human microRNAs, raising the possibility of the contribution of microRNAs
to phenotypic diversity in humans. This in-depth survey of CNVs across the human genome provides a valuable baseline
for studies involving human genetics.
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Genetic variation in the human genome exists in different
forms. Recent studies have shown that variations exist in
the human genome at various levels: the single base pair,1
the kilobase pair,2–4 and tens to thousands of kilobase
pairs.5–8 Extensive studies, including the recently pub-
lished haplotype map from HapMap,1 have identified mil-
lions of SNPs in the human genome. Three recent studies
that used the SNP data each identified several hundred
sites of deletion in the human population; however, gains
could not be deduced from this data set.2–4 By use of a
fosmid paired-end sequence analysis, a comprehensive
comparison between two genomes quantified 241 sites of
insertion or deletion.8 By use of array comparative ge-
nomic hybridization (array CGH) techniques, large-scale
copy-number variations (CNVs) were demonstrated in a
fraction of the human genome.5,6 Each of these studies
added to our knowledge about CNVs in the human pop-
ulation, but with little overlap in findings.9 Thus, many
characteristics of CNVs in the human population remain
unknown, such as the total number, genomic positions,
gene content, frequency spectrum, and patterns of linkage
disequilibrium with one another. Understanding CNVs is
critical for the proper study of disease-associated changes
because segmental CNVs have been demonstrated in de-
velopmental disorders and susceptibility to disease.10
Therefore, analysis of CNVs at the whole-genome level is
required to create a baseline of human genomic variation.
In this study, using a whole-genome tiling-path BAC array
CGH approach,11 we measured large scale (140 kb) seg-
mental gains and losses in 1100 individuals to expand our
knowledge about CNVs and to estimate the extent of this
form of variation in the human population.
Material and Methods
DNA Samples
Samples were collected and were rendered anonymous. These
samples included 16 from healthy blood donors, 51 from a British
Columbia Cancer Agency (BCCA) screening program, and 26 B-
lymphoblast DNA samples encompassing 16 distinct ethnic
groups from the Human Variation Collection and 14 CEPH ped-
igree samples from the Coriell Cell Repository (National Institute
of General Medical Sciences, Camden, NJ). The DNA samples
from cell lines were included to represent diverse ethnic popu-
lations. The 51 samples from the BCCA screening program in-
cluded 19 from a breast cancer screening program and 32 from
a colon cancer screening program. These were constitutional DNA
samples obtained from blood that did not contain any neoplastic
cells, and none showed CNV association with BRCA1 (MIM
113705), BRCA2 (MIM 600185), APC (MIM 175100), MSH2 (MIM
609309), or MSH6 (MIM 600678). Only 2 of the 32 samples from
the colon cancer screening program showed CNV association
with MLH1 (MIM 120436). In addition, no CNVs were associated
with a specific sample type or source, which suggests no obvious
selection bias. In total, 105 DNA samples (from 44 males and 61
females) were included in this study (table 1), 95 of which were
used for CNV discovery. DNA from the four grandparents of the
CEPH pedigree were included in the CNV discovery sample set,
whereas DNA from 10 other members of the family were included
only for clustering and inheritance analysis. A donor sample was
used as the male reference, and a single female sample was used
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Table 1. Samples Used in This Study
Sample Sample Sourcea Sex
S1 Coriell (NA17755), Han of L.A. M
S2 Coriell (NA10975), Mayan M
S3 Coriell (NA17392), Mexican Indian M
S4 Coriell (NA17075), Puerto Rican M
S5 Coriell (NA15724), Czechoslovakian M
S6 Coriell (NA15760), Iceland M
S7 Coriell (NA17384), African North of Sahara M
S8 Coriell (NA10469), Biaka M
S9 Coriell (NA10492), Mbuti M
S10 Coriell (NA17361), Ashkenazi Jewish M
S11 Coriell (NA11522), Druze M
S12 Coriell (NA13613), Taiwan Ami tribe M
S13 Coriell (NA13611), Taiwan Ami tribe M
S14 Coriell (NA13603), Taiwan Atayal tribe M
S15 Coriell (NA13606), Taiwan Atayal tribe M
S16 Coriell (NA11587), Japanese M
S17 Coriell (NA10540), Melanesian M
S18 Screening program, ethnicity unknown M
S19 Screening program, ethnicity unknown M
S20 Screening program, ethnicity unknown M
S21 Screening program, ethnicity unknown M
S22 Screening program, ethnicity unknown M
S23 Screening program, ethnicity unknown M
S24 Screening program, ethnicity unknown M
S25 Screening program, ethnicity unknown M
S26 Screening program, ethnicity unknown M
S27 Screening program, ethnicity unknown M
S28 Screening program, ethnicity unknown M
S29 Screening program, ethnicity unknown M
S30 Screening program, ethnicity unknown M
S31 Screening program, ethnicity unknown M
S32 Screening program, ethnicity unknown M
S33 Donor, ethnicity unknown M
S34 Donor, ethnicity unknown M
S35 Donor, ethnicity unknown M
S36 Donor, ethnicity unknown M
S37 Coriell (NA17766), Han of Los Angeles F
S38 Coriell (NA17076), Puerto Rican F
S39 Coriell (NA15729), Czechoslovakian F
S40 Coriell (NA15766), Icelandic F
S41 Coriell (NA17348), African South of Sahara F
S42 Coriell (NA10471), Biaka F
S43 Coriell (NA11521), Druze F
S44 Coriell (NA10539), Melanesian F
S45 Screening program, ethnicity unknown F
S46 Screening program, ethnicity unknown F
S47 Screening program, ethnicity unknown F
S48 Screening program, ethnicity unknown F
S49 Screening program, ethnicity unknown F
S50 Screening program, ethnicity unknown F
S51 Screening program, ethnicity unknown F
S52 Screening program, ethnicity unknown F
S53 Screening program, ethnicity unknown F
S54 Screening program, ethnicity unknown F
S55 Screening program, ethnicity unknown F
S56 Screening program, ethnicity unknown F
S57 Screening program, ethnicity unknown F
S58 Screening program, ethnicity unknown F
S59 Screening program, ethnicity unknown F
S60 Screening program, ethnicity unknown F
S61 Screening program, ethnicity unknown F
S62 Screening program, ethnicity unknown F
(continued)
Table 1. (continued)
Sample Sample Sourcea Sex
S63 Screening program, ethnicity unknown F
S64 Screening program, ethnicity unknown F
S65 Screening program, ethnicity unknown F
S66 Screening program, ethnicity unknown F
S67 Screening program, ethnicity unknown F
S68 Donor, ethnicity unknown F
S69 Donor, ethnicity unknown F
S70 Donor, ethnicity unknown F
S71 Donor, ethnicity unknown F
S72 Donor, ethnicity unknown F
S73 Donor, ethnicity unknown F
S74 Donor, ethnicity unknown M
S75 Screening program, ethnicity unknown F
S76 Screening program, ethnicity unknown F
S77 Coriell (NA17393), Mexican Indian F
S78 Donor, ethnicity unknown F
S79 Donor, ethnicity unknown F
S80 Donor, ethnicity unknown F
S81 Screening program, ethnicity unknown F
S82 Screening program, ethnicity unknown F
S83 Screening program, ethnicity unknown F
S84 Screening program, ethnicity unknown F
S85 Screening program, ethnicity unknown F
S86 Screening program, ethnicity unknown F
S87 Screening program, ethnicity unknown F
S88 Screening program, ethnicity unknown F
S89 Screening program, ethnicity unknown F
S90 Screening program, ethnicity unknown F
S91 Screening program, ethnicity unknown F
F1 Coriell (NA11917, paternal grandfather), Utah M
F2 Coriell (NA11918, paternal grandmother), Utah F
F3 Coriell (NA11919, maternal grandfather), Utah M
F4 Coriell (NA11920, maternal grandmother), Utah F
F5b Coriell (NA10842, dad), Utah M
F6b Coriell (NA10843, mom), Utah F
F7b Coriell (NA11909, son), Utah M
F8b Coriell (NA11910, daughter), Utah F
F9b Coriell (NA11911, daughter), Utah F
F10b Coriell (NA11912, son), Utah M
F11b Coriell (NA11913, son), Utah M
F12b Coriell (NA11915, daughter), Utah F
F13b Coriell (NA11916, son), Utah M
F14b Coriell (NA11921, daughter), Utah F
a Coriell Cell Repository (Coriell) sample numbers are shown in
parentheses.
b These 10 CEPH family samples were not included in the CNV discovery
set of 95.
only in control experiments. Genomic DNA from donors was
extracted from whole blood by use of the QIAamp DNA Blood
Maxi Kit (QIAGEN) and was quantified by spectrophotometry
(ND-1000 [NanoDrop]).
BAC Array CGH Analysis
DNA labeling and hybridization was performed as described else-
where,11 with slight modifications. In brief, 200 ng of sample and
reference DNA were differentially labeled with Cyanine 3–dCTP
and Cyanine 5–dCTP (Perkin Elmer Life Sciences). The random
priming reaction was incubated in the dark at 37C for 16–18 h.
DNA samples were then combined, and unincorporated nucle-
otides were removed using microcon YM-30 columns (Millipore).
Purified samples were mixed with 100 mg of human Cot-1 DNA
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Figure 1. Example of a karyogram from a hybridization experiment in this study. Custom SeeGH software was used to visualize normalized
data as log2 ratio plots.
13 The figure illustrates an example of a hybridization of a female sample versus the male reference. The log2
ratios of the data are shown as dots; the left and right vertical lines represent threshold lines for this experiment at log2 ratios of
0.18 and 0.18, respectively.
(Invitrogen) and were precipitated. DNA pellets were resuspended
in 45 ml of DIG Easy hybridization solution (Roche) containing
20 mg/ml sheared herring sperm DNA and 10 mg/ml yeast tRNA.
Sample mixture was denatured at 85C for 10 min, and repetitive
sequences were blocked at 45C for 1 h before hybridization. The
mixture was then applied onto BAC arrays containing 26,363
clones spotted in duplicate (53,856 elements with controls) on
single slides. (These clones were selected from the SMRT clone
set, to optimize tiling coverage of the genome; the clone list is
available at the SMRT Array Web site.11) Hybridization was per-
formed in the dark at 45C for ∼36 h inside a hybridization cham-
ber, followed by washing three times for 3 min each with agitation
in 0.1# saline sodium citrate (SSC) and 0.1% SDS at 45C. Arrays
were then rinsed three times for 3 min each in 0.1# SSC at room
temperature and were dried by an air stream before imaging.
Slides were scanned using a charge-coupled device–based imaging
system (arrayWoRx eAuto [Applied Precision]) and were analyzed
with the SoftWoRx Tracker Spot Analysis software (Applied Pre-
cision). The log2 ratios of the Cyanine 3 to Cyanine 5 intensities
for each spot were assessed. To remove systematic effects from
nonbiological sources that introduce bias, the ratios were then
normalized using a stepwise normalization technique.12 Custom
SeeGH software was used to visualize normalized data as log2 ratio
plots (fig. 1).13
CNV-Detection Algorithm
For each experiment, 1,398 clones from chromosomes X and Y
were removed, and the remaining data were median normalized
to remove bias introduced because of any sex-mismatched hy-
bridization. In addition, 573 clones were removed from analysis
because of printing anomalies or their shift in log2 ratios, possibly
due to homology with the X or Y chromosome, leaving a total
of 24,392 reliable clones for analysis (see the tab-delimited ASCII
file, which can be imported into a spreadsheet, of data set 1 [on-
line only]). Experimental SDs (SDautosome) were calculated for each
experiment on the basis of the log2 ratios of the 24,392 reliable
clones minus the clones removed because of low signal-to-noise
ratio (SNR) or high SD of replicate clone measures (SDclone).
Thresholds for determining CNV clones were set at a multiple of
the SDautosome value. For each experiment, clones were annotated
as uninformative if they were filtered via SNR or SDclone, as a CNV
loss if the log2 ratio was less than the negative threshold, as un-
changed if the log2 ratio was between the negative and positive
thresholds, and as a CNV gain if the log2 ratio was above the
positive threshold.
To determine the optimal values for SNR, SDclone, and the
SDautosome multiplier, eight hybridization experiments (four repeat
experiments of male reference versus the single female DNA and
four experiments between those two DNAs and two additional
DNA pools) were used. On the basis of the possible combinations
of copy-number status in the four DNA samples used, we deter-
mined the expected CNV patterns in the eight hybridization ex-
periments (table 2). The three parameters were recursively varied
until the highest proportion of CNV clones match the expected
patterns (table 2); this resulted in the filter settings of SD 1clone
, , and a stringent SDautosome multiplier of 3.3#. On0.15 SNR ! 3
Table 2. Expected CNV Patterns of Eight Hybridizations between Four DNA Samples
CNV Combinationsa Expected CNV Patternsb
MR FS MP FP MR vs. FS MR vs. FS MR vs. FS MR vs. FS MR vs. MP FS vs. MP MR vs. FP FS vs. FP
Loss Loss Loss  
Loss Loss Loss Gain  
Loss Loss Loss  
Loss Loss    
Loss Loss Gain    
Loss Loss Gain Loss  
Loss Loss Gain    
Loss Loss Gain Gain    
Loss Loss Loss      
Loss Loss      
Loss Loss Gain       
Loss Loss      
Loss      
Loss Gain       
Loss Gain Loss       
Loss Gain       
Loss Gain Gain        
Loss Gain Loss Loss      
Loss Gain Loss       
Loss Gain Loss Gain      
Loss Gain Loss       
Loss Gain        
Loss Gain Gain       
Loss Gain Gain Loss      
Loss Gain Gain       
Loss Gain Gain Gain      
Loss Loss Loss      
Loss Loss      
Loss Loss Gain       
Loss Loss      
Loss      
Loss Gain       
Loss Gain Loss       
Loss Gain       
Loss Gain Gain        
Loss Loss    
Loss  
Loss Gain    
Loss  
Gain  
Gain Loss    
Gain  
Gain Gain    
Gain Loss Loss        
Gain Loss       
Gain Loss Gain       
Gain Loss       
Gain      
Gain Gain      
Gain Gain Loss       
Gain Gain      
Gain Gain Gain      
Gain Loss Loss Loss      
Gain Loss Loss       
Gain Loss Loss Gain      
Gain Loss Loss       
Gain Loss        
Gain Loss Gain       
Gain Loss Gain Loss      
Gain Loss Gain       
Gain Loss Gain Gain      
Gain Loss Loss        
Gain Loss       
Gain Loss Gain       
Gain Loss       
Gain      
Gain Gain      
Gain Gain Loss       
Gain Gain      
Gain Gain Gain      
Gain Gain Loss Loss    
Gain Gain Loss    
Gain Gain Loss Gain  
Gain Gain Loss    
Gain Gain    
Gain Gain Gain  
Gain Gain Gain Loss  
Gain Gain Gain  
NOTE.—FP p female pool; FS p single female sample; MP p male pool; MR p single male reference.
a Possible combinations of copy-number status in the four DNA samples. Blank cells indicate no copy-number change. Gain p copy-number gain; Loss p copy-number loss.
b Expected CNV patterns of eight hybridizations between the four DNA samples. Observed experimental data were compared against these expected patterns. In each hybridization, the first
sample is expected to have a net gain in copy-number (), a net loss in copy-number (), or the same copy number (blank cell) as the second sample for a CNV with the particular combination
of copy-number status shown on the left.
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Figure 2. Detection of CNVs. The upper part illustrates a region
of CNV at 19p13.2 among four individuals. Each short line rep-
resents the average fluorescent intensity ratio between sample and
reference DNA for an individual BAC clone spotted on the array.
The left and right vertical lines represent the average threshold
for the hybridizations shown, at log2 ratios of 0.25 and 0.25. A
ratio to the right of the positive threshold line represents a copy-
number gain, whereas a ratio to the left of the negative threshold
represents a copy-number loss. Equal, greater, and fewer copies
relative to the reference DNA are shown. The lower part illustrates
a single BAC clone CNV at 7q32.1 among the four individuals; the
clone (RP11-636E12) overlaps with the IMPDH1 gene, a mutation
in which was shown to cause retinitis pigmentosa.
Figure 3. Distribution of overlapped CNVs at different recurrence
levels. The percentage of our CNV loci that overlapped with pre-
viously reported CNVs were plotted against minimum recurrence
levels of CNVs from 1 to 50 within our sample set of 95.
the basis of six self-versus-self hybridizations to calibrate array
performance, experiments with 110% uninformative data points
or with an were repeated. Normalized log2 ratioSD 1 0.12autosome
profiles were generated for the 105 individuals from hybridization
of sample DNA versus a single male reference DNA. Data points
that did not meet our SDclone or SNR criteria were annotated as
uninformative, whereas those whose average ratio exceeded the
3.3# SDautosome were identified as CNV clones (see the tab-delim-
ited ASCII file of data set 2 [online only]). CNV clones that over-
lapped in genomic coverage were considered to represent the
same CNV loci. A custom track file for uploading the identified
CNV clones to the University of California–Santa Cruz (UCSC)
Human Genome Browser is available on request. After submission
of the custom track file, clones displayed in blue, red, green, and
black represented CNVs seen once or twice, three times, four or
five times, and six or more times, respectively.
Determination of False-Positive and False-Negative Rates
To estimate our false-positive and false-negative rates in this
study, six repeat experiments (of the single female vs. the male
reference) were analyzed per our CNV algorithm (see above). In
total, 803 CNV calls were made, with 340 seen only once, 50
twice, 46 three times, 15 four times, 15 five times, and 15 six
times. Given that our false-positive results cannot exceed the total
number of calls (i.e., 803), our maximum false-positive rate is
0.5487% (803/24,392 measures # 6 experiments). By use of this
maximum false-positive rate of 0.5487%, the binomial probabil-
ity, p, of detecting the same clone twice within six experiments
by random chance is . Therefore, we concluded thatpp 0.000445
any clone detected twice or more was a true CNV in these six
repeat experiments. In theory, we expected to detect 141 true
CNVs (i.e., 50 calls seen twice, 46 seen three times, and 15 each
seen four, five, and six times) in each of the six experiments (846
calls). In practice, 463 were detected, yielding an estimated false-
negative rate of 45.3%. Although statistically a fraction of the
single-occurrence calls (those seen only once) represent true
CNVs, we conservatively considered all 340 as false-positive re-
sults, resulting in a false-positive rate of 0.2323% (340 calls/
24,392 measures # 6 experiments). In short, we tolerated this
high false-negative rate of 45.3% to achieve our very low false-
positive rate for confidence in CNV discovery.
On the basis of the false-positive and false-negative rates cal-
culated above, in a repeat of the same hybridization experiment,
one would expect to see 134 calls (803 calls/6 experiments), of
which 57 would be false-positive results (0.2323%# 24,392 mea-
sures) and 77 would be true CNVs. On the basis of our false-
negative rate, we would have missed 64 true CNVs (of 141 true
CNVs). Therefore, of a total of 141 true CNVs, the probability of
obtaining the same true CNVs in a repeat hybridization should
be 54.7% (77 of 141), and the probability of seeing those same
CNVs in a second repeat hybridization would be 54.7%# 54.7%
(42 of the 141 true CNVs). This represents 84 calls (2# 42 CNVs)
of the 268 expected total calls (134 # 2) (a 31.3% overlap). To
verify our calculated rates, three repeat hybridization experiments
were performed using the same samples. The observed overlaps
of CNV calls between the three possible comparisons were 31.3%,
28.6%, and 31.2%, which is in complete agreement with the ex-
pected value. The above calculations are summarized in figure A1
(online only). Additionally, 20 samples (F1, F2, F3, S1, S3, S4, S7,
S8, S10, S11, S12, S14, S16, S17, S33, S38, S39, S40, S41, and S44)
from the discovery set were each repeated once with a fluoro-
chrome reversal. The overlapping calls between repeats ranged
from 21% to 46%, with an average of 30%, again consistent with
the expected value from our false-positive and false-negative
rates.
Furthermore, we employed an additional platform to verify our
CNV calls. We recognize that oligonucleotide arrays are generally
not designed for measuring CNVs in certain loci, since many
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Figure 4. Overlap of CNVs with segmental duplications (SD). The
percentage of BACs that contain segmental duplications (110 kb)
is graphed against the frequency of the CNV (0 p no variation)
for two measures of human segmental duplication (WSSD and
WGAC; see the “Material and Methods” section). Segmental
duplications unique to human or chimpanzee are further
distinguished.19
segmental duplications and repeat sequences are excluded from
array design, and thus we constructed a custom oligonucleotide
array (NimbleGen Systems) covering our 3,654 CNV loci with
389,027 elements (∼2 kb spacing between elements). Five samples
(S70, S71, S72, S73, and S80) were assayed using this custom
platform. Each of these DNA samples were hybridized against the
same single male reference DNA used for BAC array analysis onto
the oligonucleotide array. As described elsewhere,14 to identify
gains or losses from the oligonucleotide array, thresholds of 2 SDs
of the mean log2 ratio for all elements in the hybridization were
used. On the basis of the detection sensitivity of BAC array CGH,15
a moving window size of 19 elements (for a total of ∼40 kb, with
∼2 kb spacing between elements) was applied. In each window,
the number of elements reporting a loss (beyond the threshold)
was subtracted from the number of elements reporting a gain.
The difference was then divided by 19—the total number of el-
ements in the window. Gains or losses were scored for results at
10.1 or !0.1, respectively. Calls from the oligonucleotide array
were then directly compared with CNVs detected by BAC array
analysis. To confirm a BAC CNV gain (or loss), at least 10 gains
(or losses) were required from the oligonucleotide probe calls cov-
ering the same BAC.
CNV Association
To obtain the genomic loci of our identified copy-number–altered
clones, we used UCSC May 2004 mapping annotations from BAC-
PAC Resources. For comparison, locations of previously identified
CNVs obtained from the Database of Genomic Variants and from
various publications were also anchored to the UCSC May 2004
assembly (from UCSC Genome Bioinformatics).2–4 These were
then converted to elements (i.e., clones) within our clone set by
comparison of chromosome number, base-pair start position, and
base-pair end position.
RefSeq gene information was downloaded from the UCSC May
2004 assembly and was viewed in relation to our CNVs. A gene
with any overlap across a CNV boundary was considered to be
associated with the CNV. Genes overlapping our CNVs were then
used to match genes downloaded from the Online Mendelian
Inheritance in Man (OMIM) Morbid Map. The locations of hu-
man microRNAs were downloaded from the Sanger miRBase da-
tabase, were converted to the UCSC May 2004 mapping anno-
tations, and were viewed in relation to our CNVs as described
above.16
Duplication Analysis
BAC clones and segmental duplication data were mapped to the
UCSC May 2004 assembly. CNV loci were assessed for duplication
content on the basis of whole-genome assembly comparison
(WGAC) and whole-genome shotgun sequence detection (WSSD)
analyses of human and chimpanzee genome assemblies.17–20 We
required 110 kb of duplicated sequence to consider a BAC as
duplicated. Lineage-specific duplications were distinguished on
the basis of human and chimpanzee-only comparisons,19 avail-
able at the Segmental Duplication Database.
Clustering Analysis
A total of 105 individuals were clustered on the basis of our CNV
clones, including 14 members of a CEPH pedigree: 4 grandparents
(already part of our 95-sample CNV discovery set), 2 parents, and
8 offspring. All clones with copy-number gains and losses were
annotated as 1 and 1, respectively. Uninformative measures
were left blank, whereas the remaining cells were annotated as
0. Hierarchical clustering of the samples with single linkage was
performed using Cluster and was visualized using Treeview21 (Ei-
sen Lab: Software Web site).
Sample Diversity
The diversity between every possible pair of individuals was cal-
culated by enumerating the number of CNVs (observed at least
three times among the 95 samples) with differing status. The pair
with the largest value was taken to be the most diverse.
Variation in genome size was determined by first enumerating
the net gain or net loss of clones (observed at least three times
among the 95 samples) within each individual compared with
our reference. The maximum variation was calculated by adding
the lowest net loss and the highest net gain. To convert this
difference in net clones to genomic size, the number of clones
was multiplied by the minimum detection sensitivity of BAC ar-
ray technology, previously shown to be 40 kb for the average-
sized BAC clone.15
Quantitative PCR
The iQ SYBR Green Supermix system (Bio-Rad) was used for quan-
titative PCR (qPCR). Primers were designed using Primer3,22 and
the primers tested are summarized in the tab-delimited ASCII file
of data set 3 (online only). In brief, 10 ng genomic DNA was used
in a 25-ml reaction with a test or reference primer pair at 600 nM.
Reactions were performed in triplicate and were repeated on dif-
ferent days by use of a Bio-Rad iCycler Optical Module (at 95C
for 10 min, then 40 cycles at 95C for 15 s and 60C for 1 min,
followed by final extension 55C for 1 min and a melting-curve
analysis). Standard curves for each primer pair were generated
using a 10-fold dilution series ranging from 0.1 ng to 100 ng.
Data analysis was performed as described by Weksberg et al.23
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Figure 5. Cluster analysis by use of a CEPH pedigree. Clustering of 105 individuals was based on the high-frequency CNV clones. The
14 CEPH pedigree members are indicated by triangles.
Results
Identification of CNVs
By application of a whole-genome tiling-path BAC array
CGH technique, pairwise comparison of DNA samples
from 95 unrelated individuals against a single reference
DNA sample identified a total of 14,711 CNV BAC clones,
averaging 155 per individual (array CGH data for all hy-
bridization experiments have been made publicly avail-
able at the Gene Expression Omnibus [series accession
number GSE5442]). This resulted in 5,132 unique clones
that span 3,654 loci throughout the mapped autosomes
(fig. 2 and the tab-delimited ASCII file of data set 2 [online
only]). To determine a confidence level for our CNVs, we
first calculated the probability of an event occurring re-
peatedly within our sample set. On the basis of our false-
positive rate of 0.23%, calculated from repeat hybridiza-
tion experiments, the probability of a random false-positive
event occurring twice or three times by chance within our
sample set of 95 was calculated ( andpp 0.02089 pp
, respectively). A detailed description of the false-0.001479
positive rate calculation is given in the “Material and
Methods” section.
Second, we examined the amount of overlap with pre-
viously reported CNVs2–8,24 (fig. 3). To facilitate the com-
parison of our CNVs with previously reported CNVs, the
locations of all published CNVs were anchored to the same
human genome assembly and were mapped to elements
in our clone set. As the minimum recurrence of our CNVs
increased, so did the proportion that overlapped with pre-
viously reported CNVs (fig. 3). Below a recurrence of 3,
little overlap was seen between our study and previous
studies. This is likely because of false-positive events or
very rare CNVs. Between recurrences of 3 and 30, a steadily
increasing overlap with previous studies was observed.
This may reflect that the more frequent the CNV in the
population, the more likely it will be observed in any given
study. Beyond a recurrence of 30, no significant increase
in overlap was observed. This may reflect the differences
in the composition of each study’s population.
Twenty of the 95 experiments were repeated using fluo-
rochrome reversal. In both the original and the repeat
experiments, 771 CNV calls were observed. Of the re-
peated calls, 81% appeared at least three times in the orig-
inal CNV discovery sample set of 95. This observation
increased confidence for CNVs that were detected three
or more times within our sample set. qPCR was performed
as a quality check on a small number of loci but was not
used for large-scale validation because of the limited
throughput of single-locus analysis (see the tab-delimited
ASCII file of data set 3 [online only]). For further verifi-
cation of our calls, five separate hybridizations were re-
peated using a custom-designed oligonucleotide array cov-
ering our 3,654 loci with 389,027 elements (∼2 kb spacing
between elements) (see the “Material and Methods” sec-
tion). In the five experiments, 265 CNV calls were con-
firmed by the oligonucleotide array analysis. Of these CNV
calls, 83% were among CNVs detected three or more times
in the original CNV discovery set of 95.
We next assessed whether our CNVs coincided with seg-
mental duplications in the genome. To achieve this, we
evaluated the segmental-duplication content of the CNVs
detected in this study, comparing it against both human
and chimpanzee sequences, since there is a significant cor-
relation between contemporary human genome structural
variation and historical segmental duplications6–8 (fig. 4).
As the frequency of the CNV increased, so did the en-
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Figure 6. Distribution of CNV clones. High-frequency CNV clones are shown as dots to the right of each chromosome; red, green, and
black dots represent presence in three, four or five, and six or more individuals, respectively. Dots to the left of the chromosomes
represent locations of CNVs that overlap microRNAs (red dots) and select cancer genes (black dots).
richment with segmental duplication. This trend in-
creased confidence for CNVs that were observed three or
more times in this sample set. We calculated a 5.7-fold
duplication enrichment for the most common variants
(5 occurrences in the 95 individuals), which is similar
to previous estimates.7,8 Interestingly, the effect was most
dramatic (a 12.1-fold increase) for duplications that arose
specifically within human.19 In contrast, no enrichment
was observed among chimpanzee-only segmental dupli-
cations (fig. 4). Elsewhere, we reported an apparent asym-
metry with respect to deletion and de novo duplication;
65% of duplications found only in chimpanzee appeared
to arise as the result of de novo duplication in the human
lineage, as opposed to deletion of a shared duplication in
a common ancestor of human and chimpanzee.19 As a
result, chimpanzee-only duplications were not expected
to be polymorphic in the human lineage.
We also used clustering analysis to assess our CNV calls.
We identified the CNVs present within a CEPH family.
Clustering of these samples in combination with our orig-
inal data set samples showed clear grouping of the CEPH
family (fig. 5).
The results from the multiple approaches described
above collectively support the presence of novel CNV loci.
In addition, the overlaps with previously reported CNVs
and segmental duplications, the repeated CNV calls from
www.ajhg.org The American Journal of Human Genetics Volume 80 January 2007 99
Figure 7. Detection of immunoglobulin variations. The three
parts illustrate expected CNVs associated with the immunoglobulin
loci at 2p11.2, 14q32.33, and 22q11.22 (top, middle, and bottom,
respectively). The left and right vertical lines represent the average
threshold for the hybridizations shown, at log2 ratios of 0.2 and
0.2. An equal intensity ratio falls on the middle line (log2 ratio
of 0), a ratio to the right of the positive threshold line represents
a copy-number gain, and a ratio to the left of the negative thresh-
old represents a copy-number loss. chr p Chromosome.
Figure 8. Inheritance of CNVs at five olfactory receptor loci in
14 members of a CEPH pedigree. The five loci (and clones), in the
order shown, are OR2A1 (RP11-466J6), OR2Z1 (RP11-367L15 and
RP11-282G19), OR4K1 (RP11-449I24 and CTD-2024K23), OR4M1
(RP11-597A11), and OR4Q3 (RP11-490A23).  p Copy-number
loss; p copy-number gain; 0p no copy-number change; UIp
uninformative. Male and female family members are shown as
squares and circles, respectively.
replicate BAC array CGH experiments and oligonucleotide
array hybridizations, the clustering of related individuals
on the basis of their CNVs, and the qPCR verification of
CNV loci sampled further support their existence. How-
ever, the prevalence of these CNVs in the human popu-
lation can be confirmed only by their presence in multiple
individuals. We placed the highest level of confidence in
their prevalence when multiple occurrences were ob-
served—for example, 800 loci appeared three or more
times in our sample set of 95 individuals. We do not rule
out the possibility that true CNVs exist among the loci
that we observed at only single and double occurrences
in our sample set, since they may represent infrequent
events, and a larger sample size will be required to confirm
their frequency in the population.
We focused on the high-frequency CNVs (i.e., those
found in at least 3 of 95 individuals) for further analysis.
There were a total of 9,848 high-frequency CNVs anno-
tated in the 95 individuals analyzed, averaging ∼104 per
individual. These represent 800 unique loci in the human
genome (fig. 6). Strikingly, when these 800 loci are com-
pared with known CNVs, 23% overlap with previously
reported CNVs and 77% are novel. The genomic distri-
bution of the 800 CNVs showed no apparent correlation
with GC content, imprinted regions, recombination rates,
or gene density. Nonrandom somatic alterations—such as
the three CNVs associated with immunoglobulin gene re-
arrangement at chromosomal subbands 2p11.2, 14q32.33,
and 22q11.22 (fig. 7)—were detected and removed from
further analysis, whereas random somatic alterations not
reflecting germline status are not expected to appear
recurrently.
Genomic Diversity within the Sample Population
We next examined the genomic diversity within our sam-
ple set. The 800 high-frequency CNV loci (or 1,005 BAC
clones) were calculated to span a minimum of 40 Mb of
DNA (calculated on the basis of BAC array CGH minimum
detection sensitivity of 40 kb per clone15). This equates to
∼1.5% of the mapped human autosomes25 that were able
to withstand CNV within our sample set. This did not take
into account the percentage of single- and double-occur-
rence loci that represented true CNVs. The two most di-
verse samples were S73 and S83. They differed at 266 of
the high-frequency CNV loci. Then, we asked the ques-
tion, What is the greatest difference in genome size be-
tween two samples within our set? S55 has the highest
net gain of CNV clones, at 97, whereas S83 has the highest
net loss of CNV clone, at 131. Comparison of these ge-
nomes revealed a difference of 228 clones, representing a
difference of at least 9 Mb in genomic size between these
two individuals.
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Table 3. Sensory-Related Genes Associated with CNVs
Chromosome
Band
Gains
and
Lossesa Gene(s)b Productc Diseasec
Clone(s) in
Locusd
1p36.31 25 TAS1R1 Sweet taste receptor T1r isoform a,b,c,d … RP11-58A11,
RP11-719E21
3p21.31 18 GNAT1 Guanine nucleotide binding protein, alpha Night blindness,
congenital
stationary
RP11-787O14
7q32.1 5 IMPDH1 Inosine monophosphate dehydrogenase 1
isoform a,b
Retinitis pigmen-
tosa-10
RP11-636E12
7q32.1 3 OPN1SW Opsin 1 (cone pigments), short-wave-
sensitive
Colorblindness,
tritan
RP11-638M14
7q35 54 OR2A12, OR2A14,
OR2A2, OR2A25,
OR2A5, OR2A1,
OR2A42, OR2A7
Olfactory receptor, family 2, subfamily A … RP11-703N5,
RP11-466J6
8p23.3 5 OR4F21, OR4F29 Olfactory receptor, family 4, subfamily F … RP11-418D21
11q11 8 OR4C6, OR4P4,
OR4S2, OR5D13
Olfactory receptor, family 4, subfamily C,P,S,D … RP11-626N6
11q12.3 3 ROM1 Retinal outer segment membrane protein 1 Retinitis pigmen-
tosa, digenic
RP11-484M5
12p13.2 3 TAS2R14, TAS2R44,
TAS2R48,
TAS2R49, TAS2R50
Taste receptor, type 2, member
14,44,48,49,50
… RP11-202N1
12q13.2 3 OR6C2, OR6C4,
OR6C68, OR6C70
Olfactory receptor, family 6, subfamily C … RP11-222A15
14q11.2 61 OR4M1, OR4Q3,
OR4K1, OR4K2,
OR4K5, OR4N2,
OR4K13, OR4K14,
OR4K15
Olfactory receptor, family 4, subfamily
M,Q,K,N
… RP11-597A11,
RP11-490A23,
RP11-449I24,
CTD-2024K23
15q11.2 26 OR4M2, OR4N4 Olfactory receptor, family 4, subfamily M,N … RP11-281J20
16p13.3 7 OR1F1 Olfactory receptor, family 1, subfamily F … RP11-680M24
17q25.3 18 ACTG1, FSCN2 Actin, gamma 1 propeptide; fascin 2 Deafness, autosomal
dominant 20/26;
retinitis pigmen-
tosa-30
RP11-730A9,
RP13-550B21
19p13.2 62 OR2Z1 Olfactory receptor, family 2, subfamily Z … RP11-282G19,
RP11-367L15
22q11.1 15 OR11H1 Olfactory receptor, family 11, subfamily H … RP11-561P7
22q12.3 5 MYH9 Myosin, heavy polypeptide 9, nonmuscle Deafness, autosomal
dominant 17
RP11-108P21
a Total number of copy-number gains and losses observed for a CNV locus.
b Sensory-related gene(s) overlapping a CNV locus.
c Gene product(s) and associated disease(s) according to ReqSeq of the UCSC May 2004 assembly and the OMIM Morbid Map.
d Clone or overlapping clones in a CNV locus.
CNV-Associated Genes
We next identified candidate genes whose dosage may be
affected by the 800 CNV loci (fig. 6 and the tab-delimited
ASCII file of data set 2 [online only]). In total, 1,673
RefSeq-annotated genes overlapped 546 of the 800 CNV
loci. First, we looked for the CNV containing the AMY1A-
AMY2A (MIM 104700; MIM 104650) amylase locus, which
was a frequently observed copy-number polymorphism.5
This clone was found to be gained in seven individuals
and to be lost in five individuals in our sample set (see
the tab-delimited ASCII file of data set 2 [online only]).
Intriguingly, many genes possibly involved in the senses
were found to associate with our CNVs, including a large
group of olfactory receptor genes (table 3). In fact, the
CNVs associated with olfactory receptor loci segregated in
a Mendelian manner in the CEPH family (fig. 8). We also
observed genes associated with taste (TAS2R and TAS1R1
[MIM 606225], encoding taste receptors), hearing (ACTG1
[MIM 102560] and MYH9 [MIM 160775]), and sight
(OPN1SW [MIM 190900], encoding the short-wave–
sensitive cone pigment; GNAT1 [MIM 139330], related to
night blindness; and FSCN2 [MIM 607643], IMPDH1 [MIM
146690], and ROM1 [MIM 180721], linked to retinitis pig-
mentosa) (table 3). In addition, the genes encoding rhesus
blood group and defensins were also observed within
these common CNVs (see the tab-delimited ASCII file of
data set 2 [online only]).
Surprisingly, many genes associated with disease and
susceptibility to disease were also found to have CNV
among our sample population. For example, a 630-kb re-
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Table 4. Select Examples of CNVs Associated with Cancer-Related Genes
Chromosome
Band Gains and Lossesa Gene(s)b Productc Clone(s) in Locusd
1p36.33 49 SKI V-ski sarcoma viral oncogene homolog RP11-83K22, RP11-181G12
1p36.32 12 TP73 Tumor protein p73 RP11-631K6
1p36.31 16 TNFRSF25 Tumor necrosis factor receptor superfamily, RP11-58A11
1p32.3 32 RAB3B RAB3B, member RAS oncogene family RP11-469M21, RP11-91A18
1p13.3 6 VAV3 Vav 3 oncogene RP11-480L11
2q14.2 18 RALB V-ral simian leukemia viral oncogene homolog B RP11-818M2
2q37.3 6 BOK BCL2-related ovarian killer RP11-343P10
3p21.31 20 NAT6, TUSC2, TUSC4 Putative tumor suppressor FUS2, tumor suppressor
candidates 2 & 4
RP11-787O14, RP13-487A19
4q31.1 3 RAB33B RAB33B, member RAS oncogene family RP11-124P22
6q21 3 C6orf210 Candidate tumor suppressor protein RP11-601O12
6q25.1 20 ESR1 Estrogen receptor 1 RP11-655H19
7p22.3 19 MAFK V-maf musculoaponeurotic fibrosarcoma oncogene RP11-16P10
7p22.3 6 MAD1L1 MAD1-like 1 RP11-325O9
8q24.21 4 MYC V-myc myelocytomatosis viral oncogene homolog CTD-2034C18
9q34.2 22 VAV2 Vav 2 oncogene RP11-352K12, RP11-651E2
10p11.23 11 MAP3K8 Mitogen-activated protein kinase kinase kinase RP11-350D11
11p15.4 15 CDKN1C Cyclin-dependent kinase inhibitor 1C RP11-494F4
11p13 3 WT1, WIT-1 Wilms tumor 1 isoform A/B/C/D, Wilms tumor as-
sociated protein
RP11-710L2
11p11.2 3 C1QTNF4 C1q and tumor necrosis factor related protein 4 RP11-425G10
11q13.1 3 MEN1 Menin isoform 1 RP11-485O9
11q13.3 6 CCND1, ORAOV1 Cyclin D1, oral cancer overexpressed 1 RP11-124K14
12q13.12 4 MLL2 Myeloid/lymphoid or mixed-lineage leukemia 2 RP11-66M13
13q31.1 4 C13orf10 Cutaneous T-cell lymphoma tumor antigen se70-2 RP11-86D5
14q32.32 3 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 RP11-455L5
16p13.3 19 AXIN1 Axin 1 isoform a/b RP11-598I20
16q22.3 3 BCAR1 Breast cancer anti-estrogen resistance 1 RP11-109K6
17p13.2 6 TAX1BP3 Tax1 (human T-cell leukemia virus type I) RP11-753P16
17q11.2 6 NF1 Neurofibromin RP11-518B17
17q21.32 3 PHB Prohibitin RP11-472H5
17q25.3 17 MAFG V-maf musculoaponeurotic fibrosarcoma oncogene RP11-634L10, RP11-712H22
17q25.3 6 C1QTNF1 C1q and tumor necrosis factor related protein 1 RP11-167N2
18p11.32 15 YES1 Viral oncogene yes-1 homolog 1 RP11-806L2
18q21.1 8 DCC Deleted in colorectal carcinoma RP11-346H17
19p13.3 6 SH3GL1 SH3-domain GRB2-like 1 RP11-406I1
19p13.3 4 TNFSF9, TNFSF7, TNFSF14 Tumor necrosis factor (ligand) superfamily,
members
RP11-526C20
19p13.3 4 VAV1 Vav 1 oncogene CTD-2200O16
19p13.11 16 RAB3A RAB3A, member RAS oncogene family RP11-512B16
19q13.33 15 PTOV1 Prostate tumor overexpressed gene 1 RP11-597G9
19q13.33 7 BAX BCL2-associated X protein isoform sigma/gamma/
epsilon/delta/beta/alpha
CTD-2017J20
19q13.33 8 RRAS Related RAS viral (r-ras) oncogene homolog RP11-264M8, RP11-808J4
20q13.13 3 BCAS4 Breast carcinoma amplified sequence 4 isoform a/b RP11-124P7
22q11.21 3 HIC2 Hypermethylated in cancer 2 CTD-2245I11
a Total number of copy-number gains and losses observed for a CNV locus.
b Gene associated with cancer, according to ReqSeq of the UCSC May 2004 assembly and the OMIM Morbid Map, overlapping a CNV locus.
c Product encoded by the gene.
d Clone or overlapping clones in a CNV locus.
gion on chromosome 3p21.3 shown to be deleted in lung
cancer was observed to be associated with copy-number
loss in 20 individuals in this study.26 This region encom-
passes the putative tumor-suppressor genes TUSC2 (MIM
607052), TUSC4 (MIM 607072), and NAT6 (MIM 607073)
(fig. 6, table 4, and the tab-delimited ASCII file of data set
2 [online only]). Many other putative oncogenes and tu-
mor-suppressor genes were also associated with CNVs,
such as the VAV2 (MIM 600428) oncogene; RAB3B (MIM
179510), of the RAS oncogene family; TNFRSF25 (MIM
603366); and CDKN1C (MIM 600856) (table 4 and the
tab-delimited ASCII file of data set 2 [online only]). In
addition to cancer-related genes, CNVs also overlapped
genes associated with a bleeding disorder (TBXA2R [MIM
188070]), diabetes mellitus (GCK [MIM 138079]), and
spinal muscular atrophy (BSCL2 [MIM 606158], SMA3
[MIM 253400], SMA4 [MIM 271150], and SMN1 [MIM
600354]), as well as with susceptibility to Alzheimer dis-
ease (A2M [MIM 103950]), coronary artery disease (LPA
[MIM 152200]), and schizophrenia (COMT [MIM 116790])
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Table 5. Select CNVs Overlapping Genes Associated with Diseases or Disease Susceptibility
Chromosome
Band
Gains and
Lossesa Gene(s)b Product(s)c Diseased
Clone(s) in
Locuse
1p36.11 7 NR0B2 Short heterodimer partner Obesity, mild, early-onset RP11-492E20
2q31.2 7 TTN Titin isoform N2-A, N2-B; isoform
novex-1,2,3
Muscular dystrophy, limb-girdle, type 2J RP11-95I17
4q11 3 SGCB Sarcoglycan, beta (43kDa dystro-
phin-associated)
Muscular dystrophy, limb-girdle, type 2E RP11-61F5
5q13.2 60 SMA3, SMA4 SMA3, SMA4 Spinal muscular atrophy-2,-1 RP11-313J5,
RP11-155O16
5q13.2 6 SMN1 Survival of motor neuron 1, telo-
meric isoform d
Spinal muscular atrophy-4 RP11-195E2
6q25.3 34 LPA Lipoprotein, Lp(a) Coronary artery disease, susceptibility to CTD-2310B5
6q26 5 PARK2 Parkin isoform 1, 2, 3 Parkinson disease, juvenile, type 2 CTD-2019O18
7p13 10 GCK Glucokinase isoform 2,3 Diabetes mellitus, neonatal-onset RP11-808H7
9q22.33 4 GPR51 G protein-coupled receptor 51 Nicotine dependence, susceptibility to RP11-786E15
11q12.3 3 BSCL2 Seipin Spinal muscular atrophy, distal, type V RP11-484M5
12p13.31 79 A2M Alpha-2-macroglobulin precursor Alzheimer disease, susceptibility to RP11-536M6
19p13.3 29 TBXA2R Thromboxane A2 receptor isoform 2 Bleeding disorder due to defective
thromboxane A2 receptor
RP11-584K12
19q13.32 3 FKRP Fukutin-related protein Muscular dystrophy, limb-girdle, type 2I RP11-422M7
22q11.21 6 COMT Catechol-O-methyltransferase isoform
S-COMT
Schizophrenia, susceptibility to RP11-651A4
a Total number of gains and losses observed for a CNV locus.
b Gene associated with disease or disease susceptibility, according to ReqSeq of the UCSC May 2004 assembly and the OMIM Morbid Map, overlapping
a CNV locus.
c Product encoded by the gene.
d Disease or disease susceptibility associated with the gene, according to the OMIM Morbid Map.
e Clone or overlapping clones in a CNV locus.
(table 5). Furthermore, we found 21 human microRNAs
that reside within 14 of the high-frequency CNV loci (fig.
6 and table 6).
Discussion
The existence of large segmental duplications and dele-
tions in the human genome has long been observed
through conventional cytogenetic analyses that use light
microscopy.27 More recent genomewide analyses with in-
creased resolutions have revealed that CNVs are present
throughout the entire human genome2–6; however, limited
genomic coverage of the arrays or the limitations of the
various techniques has restricted the discovery of CNVs
present in the sample populations. It is currently hypoth-
esized that several thousand CNVs exist within the human
genome and thus that most are yet to be discovered.9,28
Here, we used a whole-genome tiling BAC array CGH ap-
proach and identified both segmental gains and segmental
losses throughout the entire human genome. With com-
plete genome coverage and the tiling nature of our array,
we were able to identify a large number of candidate CNVs
(3,654). With a focus on only the 800 frequently occurring
loci, this study has significantly expanded our knowledge
of CNVs. A large proportion (77%) of these high-frequency
CNVs are novel; the lack of complete overlap between our
CNVs and previously reported CNVs is consistent with the
current hypothesis that thousands of CNVs exist in the
human population.
In our data set, the net difference in genomic size be-
tween two individuals could vary widely, by at least 9 Mb
in the two most diverse, representing a difference of 228
distinct CNV clones. In addition, pairwise comparison of
the high-frequency CNVs among the 95 individuals re-
vealed that the genomes of the two most diverse individ-
uals differed at 266 loci. These data demonstrate that a
significant fraction of the human genome can vary in copy
number. On the basis of our high-frequency CNV data set
and a minimum detection sensitivity for BAC array CGH
of 40 kb, at least 1.5% of the mapped human autosomes
is tolerant to CNV. This is an underestimate because the
percentage of single- and double-occurrence loci that may
represent true CNVs was not taken into account.
Over 1,500 genes were found to overlap the high-fre-
quency CNVs detected in this study. Several of these CNV-
associated genes are related to the senses, including a
group of olfactory receptor genes, multiple taste-receptor
genes, and several genes related to sight or hearing. Genes
that are well-known to have variable copy number—such
as those encoding rhesus blood group, amylases, and de-
fensins—were also observed within our common CNVs.
These associations suggest that CNVs may contribute to
phenotypic diversity in humans. Elsewhere, segmental
copy-number gains or losses have been demonstrated to
associate with developmental disorders and susceptibility
to human disease.10 Many genes associated with disease
and susceptibility to disease were found to show CNV
among the individuals within our study. These include
genes associated with diabetes mellitus or a bleeding dis-
order; cancer-related genes, such as putative oncogenes
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Table 6. MicroRNAs Overlapping CNVs
Chromosome
Band
Gains and
Lossesa microRNA(s)b Clone(s) in Locusc
3p21.2 7 hsa-let-7g, hsa-mir-135a-1 RP11-185J5, RP11-258D4
4p16.1 15 hsa-mir-95 CTD-2104N3, RP11-512D9
4p15.31 27 hsa-mir-218-1 RP11-644J20
8p21.3 9 hsa-mir-320 RP11-13A10
9q22.32 18 hsa-let-7a-1, hsa-let-7d, hsa-let-7f-1 RP11-519D15
10q26.3 21 hsa-mir-202 RP11-319M21, RP11-466F21, RP13-520O22
11q12.1 3 hsa-mir-130a RP11-781C10
17q25.3 13 hsa-mir-338 RP11-149I9
19p13.2 13 hsa-mir-199a-1 RP11-20N24, RP11-751C24
19p13.13 4 hsa-mir-181c, hsa-mir-181d, hsa-mir-23a, hsa-mir-24-2, hsa-mir-27a RP11-423F4
19q13.33 25 hsa-mir-150 RP11-21O13
20q11.22 3 hsa-mir-499 RP11-638P17
20q13.33 74 hsa-mir-124a-3 CTD-2240P21, RP11-543D7
22q11.21 6 hsa-mir-185 RP11-651A4
a Total number of gains and losses observed for a CNV locus.
b Human microRNA(s) downloaded from the Sanger miRBase database overlapping a CNV locus.
c Clone or overlapping clones in a CNV locus.
and tumor-suppressor genes; and genes associated with
susceptibility to coronary artery disease or Alzheimer dis-
ease. Like other aspects of human genetic variation, un-
derstanding of CNVs is critical for studying disease-asso-
ciated changes correctly, as illustrated in the genome
profiling of patients with mental retardation.24 Clinically
relevant alterations in copy number need to be separated
from a baseline of CNVs for gene discovery. Therefore, it
is of utmost importance when genetic association studies
of diseases are conducted that they be interpreted in the
context of baseline segmental copy-number status; CNVs
identified in this study provide a source of information
for such a baseline. Interestingly, several of our CNV loci
were also found to overlap with microRNAs. Although the
functions of microRNAs are largely unknown, they may
play a role in the regulation of various biological processes,
such as the control of development, differentiation, cell
proliferation, and apoptosis, and they have also been
linked to human diseases.29–31 Recent studies have shown
a global downregulation of microRNAs in tumors com-
pared with in normal tissues and an upregulation of
microRNA expression via copy-number changes in lym-
phoma.32,33 Our data raise the possibility that CNVs en-
compassing microRNAs contribute to human diversity
and disease susceptibility.
This comprehensive whole-genome study, identifying
both segmental gains and losses in the human population,
has significantly expanded our knowledge of CNVs. Re-
markably, the genomes of the two most diverse individ-
uals within this study differed by at least 9 Mb in size, or
266 loci in content. In addition, on the basis of our high-
frequency CNV data set, at least 1.5% of the human ge-
nome is tolerant of CNV. However, with the lack of com-
plete overlap between our CNVs and those identified
elsewhere and the hypothesis that thousands of CNVs ex-
ist in the human genome, this comprehensive study is
still an early step toward a more complete understanding
of CNVs within the human population, and more studies
are needed to examine the functional roles of CNVs.
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Cluster and Treeview)
Gene Expression Omnibus (GEO), http://www.ncbi.nlm.nih.gov/
geo/
miRBase, http://microrna.sanger.ac.uk/sequences/
OMIM, http://www.ncbi.nlm.nih.gov/Omim/ (for BRCA1,
BRCA2, APC, MSH2, MSH6, MLH1, AMY1A, AMY2A, TAS1R1,
ACTG1, MYH9, OPN1SW, GNAT1, FSCN2, IMPDH1, ROM1,
TUSC2, TUSC4, NAT6, VAV2, RAB3B, TNFRSF25, CDKN1C,
TBXA2R, GCK, BSCL2, SMA3, SMA4, SMN1, A2M, LPA, and
COMT)
OMIM Morbid Map, ftp://ftp.ncbi.nih.gov/repository/OMIM/
morbidmap
Segmental Duplication Database, http://humanparalogy.gs
.washington.edu
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SMRT Array, http://www.bccrc.ca/arraycgh/
UCSC Genome Bioinformatics, http://genome.ucsc.edu/ (for May
2004 assembly)
UCSC Human Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgGateway
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